A systematic assessment on emerging drug in the treatment of non-small cell lung cancer -pembrolizumab
Crossref DOI link: https://doi.org/10.30574/wjarr.2025.25.3.0928
Published Online: 2025-03-30
Update policy: https://doi.org/10.30574/wjarr.ourcrossmarkpolicy
Rakshith HT,
S Lohita,
Anvil Preem Rebello,
